Get the Stockscreener App
0.952
11.85%
-0.128
After Hours:
1.01
0.058
+6.09%
Vor Biopharma Inc stock is traded at $0.952, with a volume of 591.37K.
It is down -11.85% in the last 24 hours and down -28.96% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
See More
Previous Close:
$1.08
Open:
$1.06
24h Volume:
591.37K
Relative Volume:
0.84
Market Cap:
$118.79M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-0.5805
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
-27.88%
1M Performance:
-28.96%
6M Performance:
+14.24%
1Y Performance:
-58.06%
1-Day Range:
$0.95
$1.15
1-Week Range:
$0.95
$1.35
52-Week Range:
$0.63
$2.43
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
0.952 | 118.79M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Vor Biopharma: Short On Cash, Too Much Uncertainty For Now (VOR) - Seeking Alpha
Vor biopharma chief medical officer sells $3,162 in stock By Investing.com - Investing.com Canada
Vor biopharma chief medical officer sells $3,162 in stock - Investing.com India
Vor biopharma’s chief medical officer sells $3,498 in stock By Investing.com - Investing.com Nigeria
Vor biopharma's chief medical officer sells $3,498 in stock - MSN
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $11.36 - MarketBeat
Following A 1.65% Weekly Incline, Is It Still A Buy For Nerdy Inc (NYSE: NRDY)? - Marketing Sentinel
Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Should Energy Vault Holdings Inc (NYSE: NRGV) Rally After -60.12% Drop From High? - Marketing Sentinel
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL): How Can A Stock Be Up 7.83% Year To Date, But Still Loser - Marketing Sentinel
Vor Biopharma revises stock option exercise prices By Investing.com - Investing.com Canada
Vor Biopharma revises stock option exercise prices - MSN
VOR Shares Experience Surge in Value - Knox Daily
Vor Biopharma Approves Stock Option Repricing Strategy - TipRanks
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Vor Biopharma (NYSE:VOR) Shares Down 5.6% – What’s Next? - Defense World
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Inside Vor Bio's Strategic Update: Key Revelations Expected at Oppenheimer Conference - StockTitan
Vor Biopharma Inc (NASDAQ:VOR) Down -3.07% Over A Week, Now Can The Stock Hit Well Above -$0.0450? - Marketing Sentinel
SEC Form 424B3 filed by Vor Biopharma Inc. - Quantisnow
Now Is A Good Time To Buy Vor Biopharma Inc (NASDAQ: VOR) - Marketing Sentinel
A -292.16% Or Greater Growth Is Projected For Vor Biopharma Inc (NASDAQ: VOR) - Marketing Sentinel
Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $11.36 - MarketBeat
American Battery Technology Regains Compliance with Nasdaq Listing RuleAmerican Battery Technology Company (ABAT) has recently received a Notification Letter from the Nasdaq Stock Market LLC confirming the company’s compliance with Listing Rule - Defense World
Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by StockNews.com - Defense World
Arcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.com - Defense World
AngioDynamics (ANGO) to Host NanoKnife Investor Event - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Allurion Technologies (NYSE: ALUR) Enters into Omnibus Amendment to Amend Note Purchase Agreement and RIFAsOn January 7, 2025, Allurion Technologies, Inc. (NYSE: ALUR) and Allurion OpCo entered into an Omnibus Amendment with various entitie - Defense World
Vor Biopharma Strengthens Board with New Appointment - TipRanks
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors - GlobeNewswire Inc.
Vor Bio Strengthens Board with Biotech Investor Erez Kalir Following Reid Hoffman PIPE Financing - StockTitan
Enbridge (TSE:ENB) Price Target Raised to C$64.00 at Barclays - Defense World
Vor biopharma sees significant stock acquisition by Reid Hoffman - Investing.com South Africa
Vor Biopharma's chief medical officer sells shares worth $12,917 By Investing.com - Investing.com Australia
Vor Biopharma's chief medical officer sells shares worth $12,917 - Investing.com India
Vor Biopharma’s chief medical officer sells shares worth $12,917 By Investing.com - Investing.com Nigeria
Vor Biopharma Inc. (NYSE:VOR) Insider Sells $12,917.50 in Stock - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc - GuruFocus.com
Vor Biopharma’s SWOT analysis: promising AML therapy stock faces pivotal year - Investing.com Nigeria
Vor Biopharma's SWOT analysis: promising AML therapy stock faces pivotal year By Investing.com - Investing.com South Africa
Vor Biopharma's SWOT analysis: promising AML therapy stock faces pivotal year - Investing.com
Vor Biopharma Inc. announced that it has received $55.55 million in funding from RA Capital Management, L.P. - Marketscreener.com
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.13%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):